LncRNA NEAT1-FOXO3信号轴在Fuchs角膜内皮营养不良中的作用和机制研究
批准号:
82101092
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
窦圣乾
依托单位:
学科分类:
角膜及眼表疾病
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
窦圣乾
中文摘要
Fuchs内皮营养不良(FECD)是角膜内皮功能失代偿的常见病因,角膜移植是其目前唯一治疗手段,其机制尚未完全明确。前期我们通过人角膜内皮单细胞和普通转录组测序分析,结合功能实验发现:(1)长链非编码RNA NEAT1在正常角膜内皮中高表达,但在FECD患者和小鼠模型中显著下降;(2)FECD小鼠模型中,干扰Neat1会加重角膜内皮损伤程度,而过表达可缓解损伤症状;(3)NEAT1可正向调控关键抗氧化因子FOXO3的表达,影响角膜内皮细胞的抗氧化能力。由此提示,NEAT1可通过FOXO3调控角膜内皮细胞的氧化还原稳态,进而影响FECD的发生发展。因此,本课题拟结合细胞氧化损伤模型、FECD动物模型和敲除小鼠,明确NEAT1在FECD发病过程中的具体功能,阐明NEAT1-FOXO3信号轴参与调控角膜内皮细胞氧化应激反应和FECD发生发展的作用机制,为临床诊断和干预提供新的研究思路和潜在靶点。
英文摘要
Fuchs endothelial corneal dystrophy (FECD) is a common cause of corneal endothelial functional decompensation, and corneal transplantation is the only way to restore vision loss in FECD patients, but its mechanism is not fully understood. In preliminary studies, based on the single-cell and bulk transcriptomic analysis of human corneal endothelia and functional assays, we found that: (1) The long non-coding RNA (lncRNA) NEAT1 were highly expressed in normal corneal endothelium, but significantly decreased in FECD patients and mouse models; (2) Knockdown of Neat1 exacerbated the damage of mouse corneal endothelium, while overexpression diminished the symptoms of corneal endothelial injury; (3) NEAT1 could positively regulate the expression of the key antioxidant factor, FOXO3, then affected the antioxidant ability of corneal endothelial cells. It indicated that NEAT1 might regulate the cellular redox homeostasis of corneal endothelium by targeting FOXO3, and then affected the occurrence and development of FECD. Therefore, this project intends to combine cellular oxidative damage models, FECD animal models and Neat1 knockout mice to clarify the functional role of NEAT1 in the pathogenesis of FECD, and the molecular mechanism of NEAT1-FOXO3 axis in regulating oxidative stress response of corneal endothelial cells as well as the occurrence and progression of FECD, providing new ideas and potential targets for clinical intervention.
Fuchs内皮营养不良(FECD)是角膜内皮功能失代偿的常见病因,是世界范围内角膜移植术的主要适应症。该病病因复杂,机制尚未完全明确。本课题组前期通过人角膜内皮单细胞和普通转录组分析,结合体内外功能验证,鉴定到在FECD中起关键调控作用的长链非编码RNA NEAT1, 并围绕该因子进行了系列研究,取得以下进展:在细胞和动物水平明确了NEAT1在FECD发病过程中的具体功能;动物模型中证实了NEAT1对FECD的治疗效果;拓展性地探索了NEAT1对小鼠角膜上皮损伤修复的作用,以全面了解NEAT1在角膜中的生理功能。截至目前,在本项目的资助下,共发表学术论文6篇、授权专利2项。项目成果有望从新的视角加深对FECD发病机制的理解,并为临床早期诊断和干预策略提供新思路和潜在靶点。
国内基金
海外基金